Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application : vimarsana.com

By Dean Seal


Mesoblast's American depositary receipts surged after the company got the go-ahead from regulators to submit a biologics license application for its remestemcel-L treatment for...

Related Keywords

United States , American , , Drug Administration , Dean Seal , Dow Jones , Markets ,